JP2013530974A5 - - Google Patents

Download PDF

Info

Publication number
JP2013530974A5
JP2013530974A5 JP2013515874A JP2013515874A JP2013530974A5 JP 2013530974 A5 JP2013530974 A5 JP 2013530974A5 JP 2013515874 A JP2013515874 A JP 2013515874A JP 2013515874 A JP2013515874 A JP 2013515874A JP 2013530974 A5 JP2013530974 A5 JP 2013530974A5
Authority
JP
Japan
Prior art keywords
insulin
human insulin
desb30 human
amino acid
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013515874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013530974A (ja
JP5931857B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/060383 external-priority patent/WO2011161125A1/en
Publication of JP2013530974A publication Critical patent/JP2013530974A/ja
Publication of JP2013530974A5 publication Critical patent/JP2013530974A5/ja
Application granted granted Critical
Publication of JP5931857B2 publication Critical patent/JP5931857B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013515874A 2010-06-23 2011-06-21 追加のジスルフィド結合を含有するインスリン誘導体 Expired - Fee Related JP5931857B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10167033.9 2010-06-23
EP10167046 2010-06-23
EP10167033 2010-06-23
EP10167046.1 2010-06-23
US35915010P 2010-06-28 2010-06-28
US61/359,150 2010-06-28
US35950010P 2010-06-29 2010-06-29
US61/359,500 2010-06-29
PCT/EP2011/060383 WO2011161125A1 (en) 2010-06-23 2011-06-21 Insulin derivatives containing additional disulfide bonds

Publications (3)

Publication Number Publication Date
JP2013530974A JP2013530974A (ja) 2013-08-01
JP2013530974A5 true JP2013530974A5 (enExample) 2014-07-10
JP5931857B2 JP5931857B2 (ja) 2016-06-08

Family

ID=44508482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013515874A Expired - Fee Related JP5931857B2 (ja) 2010-06-23 2011-06-21 追加のジスルフィド結合を含有するインスリン誘導体

Country Status (13)

Country Link
US (2) US8853155B2 (enExample)
EP (1) EP2585485A1 (enExample)
JP (1) JP5931857B2 (enExample)
KR (1) KR20130036290A (enExample)
CN (2) CN102985440B (enExample)
AU (1) AU2011269000C1 (enExample)
BR (1) BR112012033107A2 (enExample)
CA (1) CA2802510A1 (enExample)
IL (1) IL223288A0 (enExample)
MX (1) MX337549B (enExample)
RU (1) RU2598273C2 (enExample)
WO (1) WO2011161125A1 (enExample)
ZA (1) ZA201209345B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
WO2012123519A2 (en) * 2011-03-15 2012-09-20 Novo Nordisk A/S Human insulin analogues and derivatives comprising cysteine substitutions
JP2015502971A (ja) * 2011-12-21 2015-01-29 ノヴォ ノルディスク アー/エス N末端修飾インスリン誘導体
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US20180000742A1 (en) * 2015-01-29 2018-01-04 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating
SG11201803911PA (en) * 2015-12-23 2018-07-30 Univ Case Western Reserve Encapsulation of ultra-stable insulin analogues with polymer melts
CN107436311B (zh) * 2016-05-25 2021-11-19 正大天晴药业集团股份有限公司 一种鉴别胰岛素单体或胰岛素多聚体的方法
MA49116A (fr) * 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
CN113121649B (zh) * 2019-12-26 2022-10-04 李瑛� 一种新型两亲性蛋白、其制备方法及用途
CN116789801B (zh) * 2023-08-21 2023-11-14 南京赛诺生物技术有限公司 新型胰岛素衍生物及其用途
US20250154220A1 (en) * 2023-11-15 2025-05-15 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343898A (en) 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DK155690D0 (da) * 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
SV1998000125A (es) * 1997-10-24 1999-05-24 Lilly Co Eli Composiciones de insulina insoluble ref. x-11232
PL351326A1 (en) 1999-03-17 2003-04-07 Novo Nordisk As Method for acylating peptides and novel acylating agents
HUP0203475A3 (en) 1999-12-29 2005-11-28 Novo Nordisk As Method for making insulin precursors and insulin precursor analogs
DE60328112D1 (de) 2002-09-25 2009-08-06 Novo Nordisk As Verfahren zur herstellung acylierter peptide
AU2003903124A0 (en) * 2003-06-20 2003-07-10 Mark Del Borgo Analogues of heteromeric proteins
KR101159559B1 (ko) 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー/エス 単鎖インシュリン
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
US8343914B2 (en) * 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
US20090069216A1 (en) 2006-02-21 2009-03-12 Novo Nordisk A/S Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
WO2007135117A2 (en) * 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
EP2404934A1 (en) * 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
KR20100053561A (ko) * 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
PL2229407T3 (pl) 2008-01-09 2017-06-30 Sanofi-Aventis Deutschland Gmbh Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
ES2618073T3 (es) * 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
CN102245633A (zh) 2008-12-09 2011-11-16 诺沃—诺迪斯克有限公司 新的胰岛素类似物
US20120184488A1 (en) 2009-09-01 2012-07-19 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
EP2585483A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Human insulin containing additional disulfide bonds

Similar Documents

Publication Publication Date Title
JP2013530974A5 (enExample)
JP2013530702A5 (enExample)
RU2012157683A (ru) Производные инсулина, содержащие дополнительные дисульфидные связи
ES2949553T3 (es) Composición para el tratamiento de la diabetes, que contiene conjugado de análogo de insulina de acción prolongada y conjugado de péptido de secreción de insulina de acción prolongada
JP2014129355A5 (enExample)
KR102092025B1 (ko) 페길화된 옥신토모둘린 변이체
JP2011526886A5 (enExample)
RU2012128547A (ru) Дважды ацилированные производные glp-1
RU2016135543A (ru) Новые производные инсулина и их применение в медицине
AR071990A1 (es) Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto
JP2016523241A5 (enExample)
JP2014520798A5 (enExample)
JP7432361B2 (ja) ヒトインスリンまたはそのアナログのアシル化誘導体
EP2433650A3 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
CA2608311A1 (en) Glp-1 pegylated compounds
WO2008050101A3 (en) Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk
JP2013517307A5 (enExample)
JP2013523619A5 (enExample)
JP2015517459A5 (enExample)
JP2018505146A5 (enExample)
RU2013131913A (ru) Твердые композиции, содержащие агонист glp и соль n-(2-гидроксибензоил)амино)каприловой кислоты
JP2014534265A5 (enExample)
JP2016516076A5 (enExample)
JP2014510739A5 (enExample)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение